Checkpoint blockade in unresectable pleural mesothelioma: Event horizon for multimodal therapy

[摘要] The landmark CheckMate 743 clinical trial of checkpoint blockade for malignant pleural mesothelioma (MPM) was published recently in the Lancet1 and, in short order, has changed clinical practice. This multinational, multi-institutional phase 3 trial randomized patients with untreated and unresectable MPM to dual-agent checkpoint blockade with anti-programmed cell death protein 1 (PD-1) (nivolumab) plus anti-cytotoxic T-lymphocyte antigen [CTLA]-4 therapy (ipilimumab) or systemic chemotherapy with cisplatin plus pemetrexed.

[学科分类] 心脏病和心血管学

[关键词] mesothelioma;pleura;checkpoint blockade;immunotherapy;checkpoint inhibitor;nivolumab;ipilimumab